Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer
Cancer Cell · 2026-07 · 44 (7) · 1381-1400.e9
DOI: 10.1016/j.ccell.2026.04.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026-07. Verfasst von Courtney T S Kureshi und 35 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Program in Immunology, Boston, MA, USA; Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Dendritic Cells, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Hale Family Center for Pancreatic Cancer Research.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School Program in Immunology, Boston, MA, USA; Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Im…
- Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School Pr…
- Harvard Medical School Program in Immunology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA.
- Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
- Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA.
- Massachusetts General Hospital, Department of Medicine, Division of Gastroenterology, Boston, MA, USA; Dana-Farber Cancer Institute, Department of Cancer Immunology & Virology, Boston, MA, USA; Harvard Medical School, B…
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- Hale Family Center for Pancreatic Cancer Research
- Sky Foundation Inc
- Foundation for the National Institutes of Health
- Bristol-Myers Squibb Company
- Harvard Medical School Ludwig Center
- German Research Foundation
Zitieren
APA
Kureshi, C. T. S., Walsh, M. J., Kureshi, R., Cardot-Ruffino, V., Agardy, D. A., Ali, L. R., Dougan, J. M., Qiang, L., Shen, J., Zuo, C., Lenehan, P. J., Wang, S. J., Chang, E., Remland, J., Brais, L., Clancy, T. E., Cleary, J. M., Hornick, J. L., Huffman, B. M., …, & Dougan, S. K. (2026). Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer Cell, 44(7), 1381-1400.e9. https://doi.org/10.1016/j.ccell.2026.04.005
Vancouver
Kureshi CTS, Walsh MJ, Kureshi R, Cardot-Ruffino V, Agardy DA, Ali LR, et al. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer Cell. 2026;44(7):1381-1400.e9. doi:10.1016/j.ccell.2026.04.005
BibTeX
@article{Kureshi2026,
author = {Kureshi, Courtney T S and Walsh, Michael J and Kureshi, Rakeeb and Cardot-Ruffino, Victoire and Agardy, Dennis A and Ali, Lestat R and Dougan, James M and Qiang, Li and Shen, Jiao and Zuo, Chong and Lenehan, Patrick J and Wang, S Jennifer and Chang, Eugena and Remland, Joshua and Brais, Lauren and Clancy, Thomas E and Cleary, James M and Hornick, Jason L and Huffman, Brandon M and Mancias, Joseph D and Molina, George and Fairweather, Mark and Nowak, Jonathan A and Perez, Kimberly J and Rubinson, Douglas A and Slater, Sarah and van Dams, Ritchell and Wang, Jiping and Wolpin, Brian M and Zhao, Lei and Barrientos, Katharine and Novosiadly, Ruslan and Broz, Miranda and Singh, Harshabad and Dougan, Michael and Dougan, Stephanie K},
title = {Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {7},
pages = {1381--1400.e9},
doi = {10.1016/j.ccell.2026.04.005}
}
EUVIMED